Works by Richardson, Paul G.

Results: 216
    1

    Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial.

    Published in:
    EJHaem, 2023, v. 4, n. 4, p. 995, doi. 10.1002/jha2.759
    By:
    • Richardson, Paul G.;
    • Facon, Thierry;
    • Venner, Christopher P.;
    • Bahlis, Nizar J.;
    • Offner, Fritz;
    • White, Darrell;
    • Karlin, Lionel;
    • Benboubker, Lotfi;
    • Voog, Eric;
    • Yoon, Sung‐Soo;
    • Suzuki, Kenshi;
    • Shibayama, Hirohiko;
    • Zhang, Xiaoquan;
    • Villarreal, Miguel;
    • Twumasi‐Ankrah, Philip;
    • Labotka, Richard;
    • Rifkin, Robert M.;
    • Lonial, Sagar;
    • Kumar, Shaji K.;
    • Rajkumar, S. Vincent
    Publication type:
    Article
    2

    Selinexor: Targeting a novel pathway in multiple myeloma.

    Published in:
    EJHaem, 2023, v. 4, n. 3, p. 792, doi. 10.1002/jha2.709
    By:
    • Mo, Clifton C.;
    • Yee, Andrew J.;
    • Midha, Shonali;
    • Hartley‐Brown, Monique A.;
    • Nadeem, Omar;
    • O'Donnell, Elizabeth K.;
    • Bianchi, Giada;
    • Sperling, Adam S.;
    • Laubach, Jacob P.;
    • Richardson, Paul G.
    Publication type:
    Article
    3
    4
    5

    Overall survival with oral selinexor plus low‐dose dexamethasone versus real‐world therapy in triple‐class‐refractory multiple myeloma.

    Published in:
    EJHaem, 2021, v. 2, n. 1, p. 48, doi. 10.1002/jha2.120
    By:
    • Richardson, Paul G.;
    • Jagannath, Sundar;
    • Chari, Ajai;
    • Vogl, Dan T.;
    • Dimopoulos, Meletios A.;
    • Moreau, Philippe;
    • Dingli, David;
    • Wei, Lee‐Jen;
    • Richter, Joshua;
    • Biran, Noa;
    • Siegel, David;
    • Reichmann, William;
    • Li, Lingling;
    • Tang, Shijie;
    • Saint‐Martin, Jean‐Richard;
    • Joshi, Anita;
    • Kauffman, Michael;
    • Shah, Jatin;
    • Shacham, Sharon;
    • Lonial, Sagar
    Publication type:
    Article
    6

    Randomized, placebo-controlled, phase 3 study of perifosine combined with bortezomib and dexamethasone in patients with relapsed, refractory multiple myeloma previously treated with bortezomib.

    Published in:
    EJHaem, 2020, v. 1, n. 1, p. 1, doi. 10.1002/jha2.4
    By:
    • Richardson, Paul G.;
    • Nagler, Arnon;
    • Ben-Yehuda, Dina;
    • Badros, Ashraf;
    • Hari, Parameswaran N.;
    • Hajek, Roman;
    • Spicka, Ivan;
    • Kaya, Hakan;
    • LeBlanc, Richard;
    • Sung-Soo Yoon;
    • Kihyun Kim;
    • Martinez-Lopez, Joaquin;
    • Moshe Mittelman;
    • Shpilberg, Ofer;
    • Blake, Paul;
    • Teru Hideshima;
    • Colson, Kathleen;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Leiba, Merav
    Publication type:
    Article
    7
    8

    Deeper response predicts better outcomes in high-risk-smoldering-myeloma: results of the I-PRISM phase II clinical trial.

    Published in:
    Nature Communications, 2025, v. 16, n. 1, p. 1, doi. 10.1038/s41467-024-55308-5
    By:
    • Nadeem, Omar;
    • Aranha, Michelle P.;
    • Redd, Robert;
    • Timonian, Michael;
    • Magidson, Sophie;
    • Lightbody, Elizabeth D.;
    • Alberge, Jean-Baptiste;
    • Bertamini, Luca;
    • Dutta, Ankit K.;
    • El-Khoury, Habib;
    • Bustoros, Mark;
    • Laubach, Jacob P.;
    • Bianchi, Giada;
    • O'Donnell, Elizabeth;
    • Wu, Ting;
    • Tsuji, Junko;
    • Anderson, Kenneth C.;
    • Getz, Gad;
    • Trippa, Lorenzo;
    • Richardson, Paul G.
    Publication type:
    Article
    9
    10

    The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.

    Published in:
    European Journal of Haematology, 2012, v. 88, n. 5, p. 446, doi. 10.1111/j.1600-0609.2012.01765.x
    By:
    • Richardson, Paul G.;
    • Laubach, Jacob P.;
    • Schlossman, Robert L.;
    • Ghobrial, Irene M.;
    • Redman, Katherine C.;
    • Mckenney, Mary;
    • Warren, Diane;
    • Noonan, Kimberly;
    • Lunde, Laura;
    • Doss, Deborah;
    • Colson, Kathleen;
    • Hideshima, Teru;
    • Mitsiades, Constantine;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth C.
    Publication type:
    Article
    11
    12

    Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalan-prednisone in the phase III VISTA trial in multiple myeloma.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 5, p. 372, doi. 10.1111/j.1600-0609.2011.01599.x
    By:
    • Delforge, Michel;
    • Terpos, Evangelos;
    • Richardson, Paul G.;
    • Shpilberg, Ofer;
    • Khuageva, Nuriet K.;
    • Schlag, Rudolf;
    • Dimopoulos, Meletios A.;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Petrucci, Maria T.;
    • Samoilova, Olga S.;
    • Mateos, Maria-Victoria;
    • Magen-Nativ, Hila;
    • Goldschmidt, Hartmut;
    • Esseltine, Dixie-Lee;
    • Ricci, Deborah S.;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • van de Velde, Helgi
    Publication type:
    Article
    13

    Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: subanalysis of the phase 3 VISTA study.

    Published in:
    European Journal of Haematology, 2011, v. 86, n. 1, p. 23, doi. 10.1111/j.1600-0609.2010.01533.x
    By:
    • Dimopoulos, Meletios A.;
    • Mateos, Maria-Victoria;
    • Richardson, Paul G.;
    • Schlag, Rudolf;
    • Khuageva, Nuriet K.;
    • Shpilberg, Ofer;
    • Kropff, Martin;
    • Spicka, Ivan;
    • Palumbo, Antonio;
    • Wu, Ka Lung;
    • Esseltine, Dixie-Lee;
    • Liu, Kevin;
    • Deraedt, William;
    • Cakana, Andrew;
    • Van De Velde, Helgi;
    • San Miguel, Jesús F.
    Publication type:
    Article
    14
    15
    16

    Patient‐reported health‐related quality of life from the phase III TOURMALINE‐MM1 study of ixazomib‐lenalidomide‐dexamethasone versus placebo‐lenalidomide‐dexamethasone in relapsed/refractory multiple myeloma.

    Published in:
    American Journal of Hematology, 2018, v. 93, n. 8, p. 985, doi. 10.1002/ajh.25134
    By:
    • Leleu, Xavier;
    • Masszi, Tamas;
    • Bahlis, Nizar J.;
    • Viterbo, Luisa;
    • Baker, Bartrum;
    • Gimsing, Peter;
    • Maisnar, Vladimir;
    • Samoilova, Olga;
    • Rosiñol, Laura;
    • Langer, Christian;
    • Song, Kevin;
    • Izumi, Tohru;
    • Cleeland, Charles;
    • Berg, Deborah;
    • Lin, Huamao Mark;
    • Zhu, Yanyan;
    • Skacel, Tomas;
    • Moreau, Philippe;
    • Richardson, Paul G.
    Publication type:
    Article
    17
    18
    19
    20
    21

    Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström Macroglobulinemia.

    Published in:
    American Journal of Hematology, 2010, v. 85, n. 9, p. 670, doi. 10.1002/ajh.21788
    By:
    • Ghobrial, Irene M.;
    • Xie, Wanling;
    • Padmanabhan, Swaminathan;
    • Badros, Ashraf;
    • Rourke, Meghan;
    • Leduc, Renee;
    • Chuma, Stacey;
    • Kunsman, Janet;
    • Warren, Diane;
    • Poon, Tiffany;
    • Harris, Brianna;
    • Sam, Amy;
    • Anderson, Kenneth C.;
    • Richardson, Paul G.;
    • Treon, Steven P.;
    • Weller, Edie;
    • Matous, Jeffrey
    Publication type:
    Article
    22

    New Drugs for Myeloma.

    Published in:
    Oncologist, 2007, v. 12, n. 6, p. 664, doi. 10.1634/theoncologist.12-6-664
    By:
    • Richardson, Paul G.;
    • Mitsiades, Constantine;
    • Schlossman, Robert;
    • Munshi, Nikhil;
    • Anderson, Kenneth
    Publication type:
    Article
    23

    Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

    Published in:
    Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01149-w
    By:
    • Richardson, Paul G.;
    • Perrot, Aurore;
    • Mikhael, Joseph;
    • Martin, Thomas;
    • Beksac, Meral;
    • Spicka, Ivan;
    • Capra, Marcelo;
    • D'Agostino, Mattia;
    • Sonneveld, Pieter;
    • Bisht, Kamlesh;
    • Fukao, Taro;
    • Zhang, Rick;
    • Tada, Keisuke;
    • Tekle, Christina;
    • Macé, Sandrine;
    • Klippel, Zandra;
    • van de Velde, Helgi;
    • Moreau, Philippe
    Publication type:
    Article
    24
    25

    Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee.

    Published in:
    Blood Cancer Journal, 2022, v. 12, n. 6, p. 1, doi. 10.1038/s41408-022-00695-5
    By:
    • Kumar, Shaji;
    • Baizer, Lawrence;
    • Callander, Natalie S.;
    • Giralt, Sergio A.;
    • Hillengass, Jens;
    • Freidlin, Boris;
    • Hoering, Antje;
    • Richardson, Paul G.;
    • Schwartz, Elena I.;
    • Reiman, Anthony;
    • Lentzsch, Suzanne;
    • McCarthy, Philip L.;
    • Jagannath, Sundar;
    • Yee, Andrew J.;
    • Little, Richard F.;
    • Raje, Noopur S.
    Publication type:
    Article
    26

    Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN.

    Published in:
    2022
    By:
    • Nooka, Ajay K.;
    • Kaufman, Jonathan L.;
    • Rodriguez, Cesar;
    • Jakubowiak, Andrzej;
    • Efebera, Yvonne;
    • Reeves, Brandi;
    • Wildes, Tanya;
    • Holstein, Sarah A.;
    • Anderson Jr, Larry D.;
    • Badros, Ashraf;
    • Shune, Leyla;
    • Chari, Ajai;
    • Pei, Huiling;
    • Cortoos, Annelore;
    • Patel, Sharmila;
    • Bartlett, J. Blake;
    • Vermeulen, Jessica;
    • Lin, Thomas S.;
    • Richardson, Paul G.;
    • Voorhees, Peter
    Publication type:
    Letter
    27
    28
    29

    Single-agent belantamab mafodotin for relapsed/refractory multiple myeloma: analysis of the lyophilised presentation cohort from the pivotal DREAMM-2 study.

    Published in:
    Blood Cancer Journal, 2020, v. 10, n. 10, p. 1, doi. 10.1038/s41408-020-00369-0
    By:
    • Richardson, Paul G.;
    • Lee, Hans C.;
    • Abdallah, Al-Ola;
    • Cohen, Adam D.;
    • Kapoor, Prashant;
    • Voorhees, Peter M.;
    • Hoos, Axel;
    • Wang, Karrie;
    • Baron, January;
    • Piontek, Trisha;
    • Byrne, Julie;
    • Richmond, Scott;
    • Jewell, Roxanne C.;
    • Opalinska, Joanna;
    • Gupta, Ira;
    • Lonial, Sagar
    Publication type:
    Article
    30
    31
    32
    33
    34

    Selinexor for the treatment of multiple myeloma.

    Published in:
    Expert Opinion on Pharmacotherapy, 2020, v. 21, n. 4, p. 399, doi. 10.1080/14656566.2019.1707184
    By:
    • Podar, Klaus;
    • Shah, Jatin;
    • Chari, Ajai;
    • Richardson, Paul G;
    • Jagannath, Sundar
    Publication type:
    Article
    35

    Ixazomib for the treatment of multiple myeloma.

    Published in:
    Expert Opinion on Pharmacotherapy, 2018, v. 19, n. 17, p. 1949, doi. 10.1080/14656566.2018.1528229
    By:
    • Richardson, Paul G.;
    • Zweegman, Sonja;
    • O'Donnell, Elizabeth K.;
    • Laubach, Jacob P.;
    • Raje, Noopur;
    • Voorhees, Peter;
    • Ferrari, Renda H.;
    • Skacel, Tomas;
    • Kumar, Shaji K.;
    • Lonial, Sagar
    Publication type:
    Article
    36
    37
    38
    39
    40
    41
    42

    Melflufen for relapsed and refractory multiple myeloma.

    Published in:
    Expert Opinion on Investigational Drugs, 2020, v. 29, n. 10, p. 1069, doi. 10.1080/13543784.2020.1808884
    By:
    • Oriol, Albert;
    • Larocca, Alessandra;
    • Leleu, Xavier;
    • Hajek, Roman;
    • Hassoun, Hani;
    • Rodríguez-Otero, Paula;
    • Paner, Agne;
    • Schjesvold, Fredrik H.;
    • Gullbo, Joachim;
    • Richardson, Paul G.
    Publication type:
    Article
    43
    44
    45

    Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide.

    Published in:
    British Journal of Haematology, 2014, v. 166, n. 3, p. 401, doi. 10.1111/bjh.12909
    By:
    • Yee, Andrew J.;
    • Hari, Parameswaran;
    • Marcheselli, Raffaella;
    • Mahindra, Anuj K.;
    • Cirstea, Diana D.;
    • Scullen, Tyler A.;
    • Burke, Jill N.;
    • Rodig, Scott J.;
    • Hideshima, Teru;
    • Laubach, Jacob P.;
    • Ghobrial, Irene M.;
    • Schlossman, Robert L.;
    • Munshi, Nikhil C.;
    • Anderson, Kenneth C.;
    • Weller, Edie A.;
    • Richardson, Paul G.;
    • Raje, Noopur S.
    Publication type:
    Article
    46
    47

    Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study

    Published in:
    British Journal of Haematology, 2012, v. 158, n. 4, p. 472, doi. 10.1111/j.1365-2141.2012.09173.x
    By:
    • Jakubowiak, Andrzej J.;
    • Richardson, Paul G.;
    • Zimmerman, Todd;
    • Alsina, Melissa;
    • Kaufman, Jonathan L.;
    • Kandarpa, Malathi;
    • Kraftson, Stephanie;
    • Ross, Charles W.;
    • Harvey, Colleen;
    • Hideshima, Teru;
    • Sportelli, Peter;
    • Poradosu, Enrique;
    • Gardner, Lesa;
    • Giusti, Kathy;
    • Anderson, Kenneth C.
    Publication type:
    Article
    48
    49
    50